

# Alessandro Parisi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9397800/publications.pdf>

Version: 2024-02-01

41  
papers

668  
citations

1039880

9  
h-index

887953

17  
g-index

41  
all docs

41  
docs citations

41  
times ranked

1229  
citing authors

#	ARTICLE	IF	CITATIONS
1	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. , 2019, 7, 57.		275
2	Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A hypothesis-generating preliminary report. Thoracic Cancer, 2019, 10, 347-351.	0.8	54
3	High- and low-penetrance cutaneous melanoma susceptibility genes. Expert Review of Anticancer Therapy, 2006, 6, 657-670.	1.1	45
4	Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy. Thoracic Cancer, 2018, 9, 1623-1630.	0.8	38
5	Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study. Journal of Cancer, 2019, 10, 5926-5934.	1.2	24
6	Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter SLAVE Study. Cancers, 2020, 12, 1259.	1.7	19
7	Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. European Journal of Cancer, 2022, 171, 64-74.	1.3	19
8	Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study. Immunotherapy, 2018, 10, 643-655.	1.0	15
9	First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience. Clinical and Translational Oncology, 2020, 22, 158-162.	1.2	15
10	Multimodality Treatment in Metastatic Gastric Cancer: From Past to Next Future. Cancers, 2020, 12, 2598.	1.7	11
11	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry. European Journal of Cancer, 2022, 170, 10-16.	1.3	11
12	Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1427-1440.	1.2	10
13	Topical menthol for treatment of chemotherapy-induced peripheral neuropathy. Indian Journal of Palliative Care, 2017, 23, 350.	1.0	10
14	Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2365-2373.	1.2	9
15	Evaluating the role of FAMILY history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. OncoImmunology, 2020, 9, 1710389.	2.1	9
16	Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice. OncoTargets and Therapy, 2019, Volume 12, 2159-2170.	1.0	8
17	Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis. Case Reports in Oncological Medicine, 2019, 2019, 1-3.	0.2	8
18	What Is Known about Theragnostic Strategies in Colorectal Cancer. Biomedicines, 2021, 9, 140.	1.4	8

#	ARTICLE	IF	CITATIONS
19	How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell-Based Approaches. <i>Journal of Clinical Medicine</i> , 2021, 10, 1412.	1.0	8
20	Clinicians'™ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life" Case-Control Study. <i>Clinical Colorectal Cancer</i> , 2021, , .	1.0	8
21	The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1513-1527.	1.0	7
22	Multicentric retrospective analysis of platinum+opemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice. <i>Thoracic Cancer</i> , 2018, 9, 241-252.	0.8	6
23	Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome. <i>Case Reports in Oncological Medicine</i> , 2018, 2018, 1-4.	0.2	6
24	The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A "hypothesis-generator"™ study from clinical practice. <i>Oncology Letters</i> , 2018, 16, 7195-7203.	0.8	5
25	Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study. <i>Frontiers in Oncology</i> , 2021, 11, 712053.	1.3	5
26	Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis. <i>Clinical Colorectal Cancer</i> , 2022, 21, e162-e170.	1.0	5
27	The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study. <i>Palliative and Supportive Care</i> , 2019, 17, 82-86.	0.6	4
28	The PERSONS score: A new tool for cancer patients'™ symptom assessment in simultaneous care and home care settings. <i>Palliative and Supportive Care</i> , 2020, 18, 33-38.	0.6	4
29	Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series. <i>Journal of Addictive Diseases</i> , 2020, 38, 229-234.	0.8	4
30	Timed flat infusion of 5-fluorouracil with docetaxel and oxaliplatin as first-line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOX regimen. <i>Oncology Reports</i> , 2018, 40, 803-812.	1.2	3
31	Evaluation of Prognostic Factors for Survival in Transverse Colon Cancer. <i>Cancers</i> , 2020, 12, 2457.	1.7	3
32	Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status. <i>Cancers</i> , 2022, 14, 3003.	1.7	3
33	Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab. <i>Journal of Clinical Neuromuscular Disease</i> , 2018, 20, 99-100.	0.3	2
34	Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation. <i>Bioengineering</i> , 2019, 6, 11.	1.6	2
35	Family History of Cancer as Potential Prognostic Factor in Stage III Colorectal Cancer: a Retrospective Monoinstitutional Study. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 1094-1101.	0.6	2
36	Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report. <i>Frontiers in Oncology</i> , 2022, 12, 863639.	1.3	2

#	ARTICLE	IF	CITATIONS
37	A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?. Supportive Care in Cancer, 2021, 30, 2455.	1.0	1
38	Where are we with treatment options after first line in small cell lung cancer? A report of two opposite cases treated with CAPTEM regimen and possible perspectives. Journal of Thoracic Disease, 2018, 10, E520-E525.	0.6	0
39	A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy. Annals of Oncology, 2019, 30, iv27.	0.6	0
40	Bone recurrence in early breast cancer patients: The paradox of aromatase inhibitors induced bone resorption. Breast Disease, 2021, 40, 257-262.	0.4	0
41	First-line chemotherapy with docetaxel, oxaliplatin, and timed-flat infusion 5Fluorouracil in metastatic gastro-esophageal adenocarcinomas: The experience with FD/FOx regimen.. Journal of Clinical Oncology, 2018, 36, 178-178.	0.8	0